LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors who purchased Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (NASDAQ: STML) securities between January 19, 2017 and February 1, 2017, inclusive (the “Class Period”). Stemline investors have until April 4, 2017 to file a lead plaintiff motion.
Investors suffering losses on their Stemline investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to email@example.com.
Stemline is a clinical stage biopharmaceutical company that focuses on the discovery, acquisition, development and commercialization of proprietary oncology therapeutics in the United States.
The Complaint filed in this lawsuit alleges that throughout the Class Period Defendants made false and/or misleading statements regarding the safety of its SL-401 drug candidate, including by failing to reveal that a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect on January 18, 2017; and as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you purchased shares of Stemline during the Class Period you may move the Court no later than April 4, 2017 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at http://glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.